You must be a subscriber to see the full results of your search.
Please log in or subscribe below if you are not already a subscriber.
The Daily News subscribers get full access to more than
million names and addresses along with powerful search and download features.
Get the business leads you need with powerful searches of public records and notices.
Download listings into your spreadsheet or database.
Learn more about our services
| Search again
Editorial Results (free)
1. Merck to Pay $3.85 Billion for Hepatitis C Drug Developer
- Tuesday, June 10, 2014
TRENTON, N.J. (AP) – Merck & Co. will spend about $3.85 billion for Idenix Pharmaceuticals Inc., a small company developing hepatitis C medicines that, together with Merck's experimental drugs, could produce lucrative combo therapies that quickly cure most patients with the blood-borne virus afflicting tens of millions.
2. Report: Glaxo in Talks to Buy Indian Generic Maker
- Monday, February 9, 2009
NEW YORK (AP) - U.K. drug developer GlaxoSmithKline PLC is reportedly in talks to buy Indian generic drug developer Piramal Healthcare Ltd. for about $1.5 billion.
Late Friday, the Wall Street Journal reported that people familiar with the potential deal said the companies are at an early stage of talks. GlaxoSmithKline said it would not comment, and Piramal could not be reached for comment.